It appears that the Center directed ORA to inspect Class I firms and provided each regional/district offices with a list of 50 firms to choose from. These inspectionsappear to be in part a validation exercise of the risk based approach to only inspecting higher risk firms. We are assuming it is for the remainder of this FDA fiscal year.It may increase the likelihood that lower risk device manufacturers such as MDDS are inspected through the remainder of this year.